XML 232 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis
The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis (in thousands):
Fair Value as of December 31, 2021
Fair Value Measurements Using Inputs Considered as:
Level 1Level 2Level 3
Assets:
Derivative assets - designated as cash flow hedges (foreign currency exchange rate FX)
$243 $— $243 $— 
Derivative assets - freestanding instruments (FX)61 — 61 — 
Derivative assets - capped call derivatives106,629 — — 106,629 
Convertible notes receivable2,767 — — 2,767 
$109,700 $— $304 $109,396 
Liabilities:
Derivative liabilities - designated as cash flow hedges (FX)$1,286 $— $1,286 $— 
Derivative liabilities - freestanding instruments (FX)427 — 427 — 
Derivative liabilities - embedded exchange feature181,700 — — 181,700 
Contingent consideration arrangements98,382 — — 98,382 
$281,795 $— $1,713 $280,082 
Fair Value as of December 31, 2020
Fair Value Measurements Using Inputs Considered as:
Level 1Level 2Level 3
Assets:
Derivative assets - designated as cash flow hedges (foreign currency exchange rate “FX”)$2,893 $— $2,893 $— 
Derivative assets - freestanding instruments (FX)55 — 55 — 
Derivative assets - capped call derivatives72,302 — — 72,302 
Convertible notes receivable2,775 — — 2,775 
$78,025 $— $2,948 $75,077 
Liabilities:
Derivative liabilities - designated as cash flow hedges (FX)$14 $— $14 $— 
Derivative liabilities - freestanding instruments (interest rate swaps)74 — 74 — 
Derivative liabilities - freestanding instruments (FX)4,073 — 4,073 — 
Derivative liabilities - embedded exchange feature121,756 — — 121,756 
Derivative liabilities - other4,290 — — 4,290 
Contingent consideration arrangements103,818 — — 103,818 
$234,025 $— $4,161 $229,864 
Schedule of Recurring Fair Value Measurements Using Significant Unobservable Inputs
The following table provides a reconciliation of the beginning and ending balances of our recurring fair value measurements, using significant unobservable inputs (Level 3) (in thousands):
Capped Call Derivative AssetConvertible Notes ReceivableEmbedded Exchange Feature Derivative LiabilityOther Derivative LiabilitiesContingent Consideration Liability Arrangements
December 31, 2019$— $— $— $— $137,349 
Additions 43,096 2,691 74,951 — — 
Payments (1)
— — — — (12,868)
Changes in fair value (2) (3) (4)
29,206 84 46,805 4,290 (20,463)
Effect of changes in FX— — — — (200)
December 31, 202072,302 2,775 121,756 4,290 103,818 
Additions— — — — — 
Payments (1)
— — — — (6,000)
Changes in fair value (2) (4)
34,327 (8)59,944 (4,290)564 
Effect of changes in FX— — — — — 
December 31, 2021106,629 2,767 181,700 — 98,382 
Less current portion at December 31, 2021106,629 2,495 181,700 — 11,552 
Long-term portion at December 31, 2021$— $272 $— $— $86,830 
(1)During the year ended December 31, 2021, we paid $6.0 million under the contingent consideration arrangement for the acquisition of Miami Instruments, LLC (“Miami Instruments”). During the year ended December 31, 2020, we paid $11.8 million under the contingent consideration arrangement for the acquisition of TandemLife. Additionally, we made final payments under contingent consideration arrangements resulting from the acquisitions of two distributors.
(2)During the year ended December 31, 2021, the contingent consideration change in fair value resulted in a decrease of $8.5 million recorded to cost of sales and an increase of $9.1 million recorded to research and development. During the year ended December 31, 2020, the contingent consideration change in fair value resulted in a decrease of $13.0 million and $7.5 million recorded to cost of sales and research and development, respectively.
(3)The contingent consideration change in fair value during the year ended December 31, 2020 is primarily due to a one-year delay in the projected achievement of a certain regulatory milestone and timing of sales-based earnout payments for ImThera, and the impact of an increase in discount rates utilized in the valuation of contingent consideration. Refer to the tables below for further information regarding the fair value measurements of contingent consideration.
(4)Changes in the fair value of the embedded exchange feature derivative, capped call derivatives and other derivative liabilities are recognized in foreign exchange and other gains/(losses) in the consolidated statements of income (loss).
Schedule of Fair Value of Contingent Consideration by Acquisition
The following table provides the fair value of our Level 3 contingent consideration arrangements by acquisition (in thousands):
December 31,
20212020
ImThera$86,830 $89,436 
TandemLife11,552 8,809 
Miami Instruments— 5,573 
$98,382 $103,818 
Significant Unobservable Inputs Related to Contingent Consideration Both arrangements are Level 3 fair value measurements and include the following significant unobservable inputs as of December 31, 2021:
ImThera AcquisitionValuation TechniqueUnobservable InputRanges
Regulatory milestone-based paymentDiscounted cash flowDiscount rate3.6%
Probability of payment85%
Projected payment year2024
Sales-based earnoutMonte Carlo simulationRisk-adjusted discount rate12.4%-12.8%
Credit risk discount rate3.9% -4.6%
Revenue volatility32.5%
Probability of payment85%
Projected years of earnout2025-2028
The TandemLife business combination involved a contingent consideration arrangement composed of potential cash payments upon the achievement of certain regulatory milestones. The arrangement is a Level 3 fair value measurement and includes the following significant unobservable inputs as of December 31, 2021:
TandemLife AcquisitionValuation TechniqueUnobservable InputRanges
Regulatory milestone-based paymentDiscounted cash flowDiscount rate2.4%
Probability of payments90%
Projected payment years2022